Adenomyosis, also known as uterine adenomyoma, is a high incidence in women of childbearing age, mainly manifesting as dysmenorrhea, abnormal menstruation and infertility, and can be associated with uterine fibroids. Adenomyosis occurs in patients who have undergone uterine surgery (multiple pregnancies, deliveries, scrapings, etc.) and is more common between the ages of 30 and 50 years, with multiple scrapings being the main cause of the disease, while it is rare in women who have not had children. Currently, adenomyosis is mainly treated clinically with surgery and medication. Surgery is the most common traditional treatment for adenomyosis, including hysterectomy, simple lesion removal, and endometrial resection. Hysterectomy can treat the disease more thoroughly and with fewer complications, but it is usually used for patients without fertility requirements and with poor results of conservative treatment, but not for young women with fertility requirements; simple focal resection is more difficult and not easy to remove the lesion completely, and it is easy to recur after surgery, so many patients are unwilling to accept it. Medications include gonadotropin-releasing hormone (GnRHa), levonorgestrel, oral contraceptives, and progestins. Although hormone therapy can relieve symptoms and amenorrhea, long-term use of hormone therapy can produce adverse symptoms such as masculinization, water and sodium retention, and obesity, limiting its long-term use. Uterine artery embolization (UAE) is an emerging treatment for adenomyosis at home and abroad in recent years, which significantly improves the efficacy and avoids the adverse effects of drugs, and minimally invasive to overcome the loss of fertility and psychological burden caused by the removal of the uterus. Adenomyosis is an island of endometrium located in the myometrium, which has the same proliferation cycle as normal endometrium. UAE can block the blood supply to the lesion, causing ischemic necrosis and resorption of the lesion, and at the same time, due to the ischemia of the uterus itself, the hyperplastic myometrium shrinks, the uterus becomes smaller, and the clinical symptoms improve significantly or disappear. Indications: Patients with adenomyosis with obvious clinical symptoms such as dysmenorrhea, excessive menstrual flow, etc., who do not have good results with conservative treatment and do not want to undergo hysterectomy are eligible for UAE. Contraindications: Acute uncontrolled pelvic infection, contrast allergy, abnormal coagulation function, severe vascular disease, immunocompromised, etc.